19:20 , Nov 19, 2018 |  BC Extra  |  Financial News

NASH company Genfit planning U.S. listing

As it prepares for a readout from a Phase III study of its lead candidate to treat non-alcoholic steatohepatitis, French bellwether Genfit S.A. (Euronext:GNFT) intends to conduct a listing on a U.S. exchange. Genfit said...
17:33 , Nov 16, 2018 |  BC Week In Review  |  Company News

MaxCyte partners with Kite, CRISPR in nonviral gene editing deals

MaxCyte Inc. (LSE:MXCT) partnered with Kite Pharma Inc. and expanded an existing deal with CRISPR Therapeutics AG (NASDAQ:CRSP) to use its Flow Electroporation technology to engineer cells. Kite gains a non-exclusive license to use MaxCyte's...
17:10 , Nov 16, 2018 |  BC Week In Review  |  Company News

NICE backs Novartis' Kymriah in acute lymphoblastic leukemia

U.K.'s NICE recommended in final guidance on Nov. 15 that CAR T therapy Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) for use through the Cancer Drug Fund in patients under 25 with relapsed or refractory...
00:01 , Nov 16, 2018 |  BC Extra  |  Company News

NICE backs Novartis' Kymriah in acute lymphoblastic leukemia

U.K.'s NICE recommended in final guidance CAR T therapy Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) for use through the Cancer Drug Fund in patients under 25 with relapsed or refractory B cell acute lymphoblastic...
00:25 , Nov 14, 2018 |  BC Extra  |  Politics & Policy

Epclusa, Harvoni first alternatives on Express Scripts' new formulary

Express Scripts Holding Co. (NASDAQ:ESRX) introduced a new formulary Tuesday to help lower out-of-pocket costs and reduce dependence on rebated brand products by including authorized alternative medicines with lower list prices. HCV drugs Epclusa sofosbuvir/velpatasvir...
23:24 , Nov 7, 2018 |  BC Extra  |  Company News

Management tracks: Myovant, Alkahest

Women’s health and endocrine disease company Myovant Sciences Ltd. (NYSE:MYOV) named Kim Sablich chief commercial officer and Jeff Nornhold SVP of pharmaceutical operations and development. Sablich was VP of primary care marketing in the U.S....
02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
00:34 , Nov 3, 2018 |  BioCentury  |  Finance

Part B exposure

HHS Secretary Alex Azar's proposed changes to Medicare Part B have put at least four large biopharmas at risk of substantial U.S. revenue losses. But the lack of market reaction and the views of VCs...
19:53 , Nov 2, 2018 |  BC Week In Review  |  Company News

Tango, Gilead partner to discover immune evasion cancer targets

Tango Therapeutics Inc. (Cambridge, Mass.) and Gilead Sciences Inc. (NASDAQ:GILD) will employ Tango's functional genome-based platform to discover tumor-intrinsic immune evasion targets. Gilead will have worldwide options to five targets under the deal. Tango will...
19:49 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Gilead discontinues gastric cancer candidate andecaliximab

Gilead Sciences Inc. (NASDAQ:GILD) announced in its 3Q18 earnings that it discontinued development of andecaliximab for gastric cancer. The company said a Phase III trial showed a lack of benefit on the primary endpoint of...